Oral Agents for Advanced Hormone Receptor Positive Breast Cancer

This webinar is open to the public. You do not need to be an ACCC member to view this webinar, but you will need to create an account in order to register.  

 If You DO NOT Have an ACCC Account: 

  • To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page. 
  • ACCC and State Society Members: Click “Reset Password” to update your login information. When your password is updated, you will be redirected to the “My Profile” page.  
  • Non-members: Click “Create Account.” Once your password is created, you will be redirected to the "My Profile" page.  
  • Click “eLearning” at the top of your profile page to go back to the ACCC eLearning portal. In the box on the left side of the screen, click on the “Cart” link. 
  • The green box in the upper right corner of this page will indicate “You are registered!” for this course! 

If You Have an ACCC Account: 

  • Please click the orange “Log In” button on the left side of this screen. You will be taken to the main login page that displays your email and password. Click the “Log in” button. 
  • You will be automatically redirected back to webinar page, and the green box in the upper right corner will say that “You are registered!” for this course! 

PRO TIP: If you save your ACCC password to your computer and remain logged in, you can register for additional webinars and courses in a matter of seconds—with just one click!  

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer Users may experience difficulties accessing the webinar. 

Once you complete your registration, you will receive an email from ACCC eLearning, which contains information on how to access this webinar. For assistance with registration or if you do not receive an email, please contact registration@accc-cancer.org.

Release Date: May 25, 2021
Expiration Date: May 24, 2022
Estimated time to complete:  60 minutes

This educational activity is jointly provided by Hematology/Oncology Pharmacy Association (HOPA)  and the Association of Community Cancer Centers (ACCC) in collaboration with AXIS Medical Education.

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Target Audience

This program is designed for individuals across the cancer care team including nurses, advanced practice providers, pharmacists, physicians, and other health care professionals caring for patients with advanced or metastatic breast cancer.

Overview

The goal of this activity is to improve participants’ knowledge of, confidence, and competence in the appropriate use of oral agents for patients with HR-positive, advanced or metastatic breast cancer. Special attention will be paid to strategies to manage acquisition of, adherence to, and treatment-related adverse events of oral drug-inclusive treatment regimens as part of an interprofessional team. 

Objectives

At the end of this educational activity, participants should be able to:

1. Select appropriate evidence-based oral treatment options for patients with advanced hormone-sensitive breast cancer.  

2. Outline strategies to evaluate patients during therapy and manage potential treatment-related adverse events.

3. Recognize common barriers encountered during planning and delivery of care for patients with advanced hormone-sensitive breast cancer.

4. Outline effective approaches to engage patients and their caregivers to actively participate in shared clinical decision-making.



Faculty

Pavani Chalasani MD, MPH 
Professor of Medicine
Program Director-Hematology/Oncology Fellowship
University of Associate Arizona Cancer Center
Tucson, AZ

Elizabeth Dow-Hillgartner, PharmD, BCOP, BCPS
Clinical Pharmacist, Hematology/Oncology|UW Health
Madison, WI

Tammy Smith, MSN, FNP-C, CBCN
Nurse Practitioner
Inova Schar Cancer Institute
Breast Cancer Medical Oncology
Fairfax, VA

Accredited Continuing Education
Accreditation Statement

Jointly Accredited Provider Logo

In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


image

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


Credit Designation for Physician

AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing

AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information

For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.   

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.  

 The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: 

Name of Faculty or Presenter/Planner

Reported Financial Relationship

Pavani Chalasani, MD, MPH   

    Consultant: Eli Lilly and Company and OncoSec Medical Incorporated.

Elizabeth Dow-Hillgartner, Pharm-D, BCPS, BCOP

    Nothing to disclose

Tammy Smith, MSN, FNP-C, CBCN

    Speaker’s bureau for: AstraZeneca and Daiichi Sankyo.




The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  

Name of Planner/Manager/Reviewer

Reported Financial Relationship

Leigh M. Boehmer, PharmD, BCOP

Consultant: Pfizer, Inc.
Marilyn Haas, PhD, RN, CNS, ANP-BC

Nothing to disclose

Sandra Megally

Nothing to disclose

Dee Morgillo, MEd., MT(ASCP), CHCP

Nothing to disclose

Laurie Rappa

Nothing to disclose

Latha Shivakumar, PhD, CHCP 

Nothing to disclose

Ronald Viggiani, MD

Nothing to disclose

Disclaimer  

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

System Requirements

For the best registration and viewing experience, please use Chrome, Edge, or Safari web browsers. Internet Explorer users may experience difficulties accessing the sessions. 

Method of Participation and Request for Credit      

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. 

Pavani Chalasani MD, MPH

Associate Professor of Medicine, Program Director

University of Arizona Cancer Center, Tucson, AZ

Dr. Pavani Chalasani is an Associate Professor of Medicine and the Program Director of the Hematology/Oncology Fellowship Program at the University of Arizona Cancer Center in Tucson, Arizona. 

Elizabeth Dow-Hillgartner, PharmD, BCOP, BCPS

Clinical Pharmacist, Hematology/Oncology

UW Health Madison, WI

Dr. Elizabeth Dow-Hillgartner is a Hematology/Oncology Clinical Pharmacist at the University of Wisconsin Health System in Madison, Wisconsin. Her primary responsibilities include practice within the gastrointestinal, breast, melanoma and brain cancer ambulatory oncology clinics. 

Tammy Smith, MSN, FNP-C, CBCN

Nurse Practitioner

Inova Schar Cancer Institute Breast Cancer Medical Oncology Fairfax, VA

Tammy Smith is a family nurse practitioner. She works at INOVA Schar Cancer Institute where she specializes in both medical and surgical oncology for the treatment of breast cancer. She is a certified breast care nurse and sits on the faculty panel for breast cancer with ASCO Advantage. 

Key:

Complete
Failed
Available
Locked
Pre-Assessment
5 Questions  |  1 attempt  |  0/100 points to pass
5 Questions  |  1 attempt  |  0/100 points to pass
Course Content
Recorded 04/12/2021
Recorded 04/12/2021 After viewing the lecture, please complete the post assessment and the course evaluation to receive CE credit
Post-activity Assessment
5 Questions  |  3 attempts  |  75/100 points to pass
5 Questions  |  3 attempts  |  75/100 points to pass
Course Evaluation
13 Questions
13 Questions This evaluation must be completed to receive credit for this course. Estimated time to complete is 5 minutes.
CME/CNE/Certificate of Participation
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available Please note: If you have completed a course prior to May 2020 and need a copy of your CME or CNE certificate, please email rburtnick@accc-cancer.org and include your full name, credentials, and email address.